Publication Name	World Journal of Clinical Cases
Manuscript ID	39289
Country	Türkiye

Received	2018-04-10 09:50
Peer-Review Started	2018-04-10 10:58
To Make the First Decision	2018-04-27 02:08
Return for Revision	2018-05-15 06:49
Revised	2018-05-15 09:54
Second Decision	2018-06-07 12:08
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-06-08 23:35
Articles in Press	2018-06-08 23:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-09-16 09:10
Publish the Manuscript Online	2018-09-28 10:31

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
Manuscript Source	Invited Manuscript
All Author List	Ozkan Kanat, Hulya Ertas and Burcu Caner
ORCID	Author(s) ORCID Number Ozkan Kanat http://orcid.org/0000-0001-6973-6540 Hulya Ertas http://orcid.org/0000-0001-8306-4349 Burcu Caner http://orcid.org/0000-0003-1591-3323
Funding Agency and Grant Number
Corresponding Author	Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Faculty of Medicine, Uludag University, Gorukle, Bursa 16059, Türkiye. ozkanat@uludag.edu.tr
Key Words	Epidermal growth factor receptor; Cetuximab; Panitumumab; Human epidermal growth factor receptor 2; Anti-epidermal growth factor receptor resistance; Trastuzumab; Dual inhibition
Core Tip	We reviewed the preclinical studies exploring the role of human epidermal growth factor receptor 2 (HER2) signaling in the development of anti-epidermal growth factor receptor therapy resistance in metastatic colorectal cancer and discussed the status of clinical trials assessing the activity of HER2 inhibitors in this setting.
Publish Date	2018-09-28 10:31
Citation	Kanat O, Ertas H, Caner B. Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. World J Clin Cases 2018; 6(11): 418-425
URL	http://www.wjgnet.com/2307-8960/full/v6/i11/418.htm
DOI	http://dx.doi.org/10.12998/wjcc.v6.i11.418

Full Article (PDF)	WJCC-6-418.pdf
Full Article (Word)	WJCC-6-418.doc
Manuscript File	39289-Review.docx
Answering Reviewers	39289-Answering reviewers.pdf
Audio Core Tip	39289-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	39289-Conflict-of-interest statement.pdf
Copyright License Agreement	39289-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	39289-Language certificate.pdf
Peer-review Report	39289-Peer-review(s).pdf
Scientific Misconduct Check	39289-Scientific misconduct check.pdf
Scientific Editor Work List	39289-Scientific editor work list.pdf